Q2 2026 GVS SpA Earnings Call Transcript
Key Points
- GVS SpA (LTS:0GV5) reported a 3.3% organic growth in H1 2026, with sales reaching EUR 215 million, and all three divisions (Healthcare, Energy & Mobility, Safety) posted positive growth.
- EBITDA margin expanded by 62 basis points to 25.7%, driven by effective pricing actions that offset raw material cost increases.
- Transfusion Medicine showed strong acceleration, growing nearly 11% in H1, with momentum building from Q1 to Q2 as more product codes were certified.
- Net financial position improved by EUR 30 million year-over-year to EUR 239 million, with leverage stable at 2.2x.
- Management demonstrated agility in pricing, having learned from 2022, and expects no margin impact from geopolitical tensions in Q3.
- Negative FX impact of EUR 7.7 million in H1, primarily due to US dollar depreciation, though expected to reverse in H2.
- Adjusted net income declined to EUR 23.8 million (11.1% margin) due to higher depreciation from new plants in the UK and China.
- Production inefficiencies from the Transfusion Medicine ramp-up in Mexican plants are slightly dilutive to margins, expected to persist until year-end.
- Net working capital increased by EUR 21.7 million in H1, mainly due to higher inventory, though expected to recover in H2.
- Management kept guidance unchanged (low single-digit growth, 20-50 bps margin expansion) citing geopolitical complexity and a preference for prudence until Q3 visibility improves.
Good afternoon. This is the conference operator. Welcome and thank you for joining the GBS first half 2026 results web call.
(Operator Instructions)
Thank you. Good afternoon. Good morning to everybody. Welcome to the first half presentation of GVS. A quick snapshot on the numbers. A +3.3% organic growth versus the previous year, with sales at EUR 215 million. EBITDA at EUR 55.4 million, +2.2% versus the previous year, with a 27% margin. An improvement of 62 basis points versus the first half of the previous year. Interesting to notice that we have an acceleration in Q2 at EUR 29.5 million, with a 26.8% margin. Of course, Q2 is always one of our best Qs, but itâs interesting to see this movement. EUR 23.8 million of adjusted net income with 11.1% margin. A net financial position at EUR 239 million, with a leverage ratio of 2.2. Now we are going to the division. We can see a nice growth in all the divisions.
We have a +2.1% on healthcare, +2.4% in energy and mobility, +8.2% in safety.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
